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Abstract
Alopecia means partial or complete loss of hair from a part of the body where it exists
naturally. It affects both men and women, and its treatment depends upon its cause, age of
onset, and clinical presentation. It is divided into scarring and non-scarring alopecia. Scar-
ring alopecia includes pseudopelade of Brocq, central centrifugal cicatricial alopecia, follicu-
litis decalvans, acne keloidalis nuchae, lichen planopilaris, frontal fibrosing alopecia and
discoid lupus erythematosus, traumatic i.e., injury, radiation and post-operative scarring
alopecia and certain neoplasms. Common causes of non-scarring alopecia are androgenic
alopecia, alopecia areata, telogen effluvium, anagen effluvium, trichotillomania, traction
alopecia, pressure-induced alopecia, alopecia due to iron deficiency, thyroid disease, and
polycystic ovary syndrome. Topical remedies available are minoxidil 2 and 5%, topical &
intralesional steroids, topical sensitization, anthralin, retinoids, tacrolimus, garlic, ketocona-
zole and prostaglandin analogs. Among systemic treatments, finasteride, steroids, immuno-
suppressant like azathioprine, methotrexate, sulfasalazine, zinc sulfate and iron are widely
accepted. The phototherapies, photo-chemotherapies, platelet rich plasma (PRP) therapy,
pharmacogenetics and hair transplant are new remedies for alopecia. It is concluded that
minoxidil, finasteride, PRP, and hair transplant are the most widely being used modalities
for alopecia.
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1. Introduction
Alopecia means partial or complete loss of hair from a part of the body where it exists
naturally. It affects both men and women. According to cause it can be androgenic, autoim-
mune, traumatic, genetic, metabolic, and neoplastic. Clinically, it is divided mainly into two
categories i.e., scarring and non-scarring alopecia. Proper history taking, the onset of disease,
family history both paternal and maternal, past medical and surgical history, allergies to
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medicine, Physical examination, hair count, pull test, pluck test (trichogram), histological,
serological and immunofluorescent data will lead us to proper diagnosis of the cause and its
treatment plan. Biopsies provide diagnosis, the degree of hair shedding, type of hair, anagen to
telogen ratio and provide information regarding the potential for hair regrowth. Many treat-
ment modalities are available for treating alopecia i.e., medical and surgical. Medical treat-
ments include minoxidil 2% and 5%, topical & intralesional steroids, topical sensitization/
immunotherapy, anthralin, retinoids, tacrolimus, garlic, ketoconazole and prostaglandin ana-
logs. Among systemic treatments, finasteride, dutasteride, spironolactone, flutamide, cyproter-
one acetate, sulfasalazine, corticosteroids, immunosuppressant like azathioprine & cyclosporine,
methotrexate, biological agents, photochemotherapy, low-level light therapy, zinc, vitamins &
supplements are widely being used. Platelet-rich plasma (PRP) therapy and hair transplant are
very popular treatments now a days.
2. Topical treatment
Most common topical treatments are minoxidil, topical & intralesional steroids, topical sensiti-
zation/immunotherapy, anthralin, topical retinoids, tacrolimus, garlic, ketoconazole and pros-
taglandin analogs.
2.1. Minoxidil
Chemically, minoxidil is 2,4-diamino-6-piperidinopyimidine 3-oxide and it is being used as a
topical agent for the treatment of androgenic alopecia since 1987. Mechanism of action is not
exactly known, but it shortens telogen phase, extends anagen phase and is a hair growth
stimulator. Scalp sulfotransferase converts minoxidil into minoxidil sulfate which is the active
form of the molecule [1]. There are certainly proposed mechanisms of minoxidil actions are
vasodilation, potassium channel opening, antiandrogen, angiogenesis, the release of growth
factors, stimulation of dermal papilla, and immunosuppression [2, 3]. Topical minoxidil is
available in spray and foam forms in two strengths i.e., 2 and 5%. Its half-life is 4.2 h and effects
occur after 8 weeks andmaximum after 4 months. It should be applied twice a day for at least 4 h
to get good results. Micro-needling can be associated to enhance its efficiency. It will give good
results if the age of alopecia is less than 5 years and hair follicles are not deeply miniaturized.
Currently, Topical minoxidil is being used in patients with AGA, AA, hair transplant, scarring
alopecia, hereditary alopecia/hypotrichosis, chemotherapy-induced alopecia, and monilethrix.
Adverse effects include allergic contact dermatitis; minoxidil induced telogen effluvium, skin
irritation, and scaly changes in the scalp, isolated itching, localized or generalized hypertri-
chosis and hypotension. It is not advised in pregnant or breastfeeding mother.
2.2. Platelet rich plasma therapy
Platelet-rich plasma (PRP) therapy is a new medical technique widely being used in hair
restoration especially in cases of androgenic alopecia and alopecia areata. To prepare PRP,
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40–60 ml patient’s blood is centrifuged for 10–20 min and 2–4 ml platelet rich portion is
separated from the poor platelet plasma portion. It is injected locally in the areas of alopecia
as multiple points in the dosage of 0.1 ml/cm2with 27–30 gauge needles with 4–6 mm length. It
is repeated at 3–4 weeks intervals.
After activation, platelet alpha-granules release multiple growth factors; platelet-derived
growth factor (PDGF), transforming growth factor (TGF), vascular endothelial growth factor
(VEGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), and interleukin-1 [4].
PRP acts on stem cells at bulge area and stimulates the growth of new follicle and neovascu-
larization. No major side effects reported yet.
2.3. Topical and intralesional steroids
2.3.1. Topical corticosteroids
Topical corticosteroids are available in many formulations. These are divided into following
categories by WHO according to their potencies [5]:
(I) Ultra high: clobetasol propionate 0.05%, diflorasone diacetate 0.05%.
(II) High: amcinonide ointment 0.1%, betamethasone dipropionate ointment 0.05%, desoxi-
metasone cream/ointment 0.025%, fluocinonide cream ointment or gel 0.05%, halcino-
nide cream 0.1%.
(III) Betamethasone dipropionate 0.05%, betamethasone valerate 0.1%, diflorasone diacetate
0.05%, triamcinolone acetonide 0.1%.
(IV) Moderate: desoximetasone cream 0.05%, fluocinolone acetonate 0.025%. fludroxycortide
ointment 0.05%, hydrocortisone valerate 0.2%, triamcinolone acetonide cream 0.1%.
(V) Betamethasone dipropionate 0.02%, betamethasone valerate 0.1%, fluocinolone aceto-
nide 0.025%, fludroxycortide0.05%, hydrocortisone butyrate 0.1%, hydrocortisone vale-
rate 0.2%, triamcinolone acetonide lotion, 0.1%.
(VI) Low: Betamethasone valerate 0.05%, desonide 0.05%, fluocinolone acetonide 0.01%.
(VII) Dexamethasone sodium phosphate cream 0.1%, hydrocortisone acetate 1%, methyl-
prednisolone acetate 0.25%.
Topical corticosteroids promote maximum local action and minimum systemic side effects.
The main mechanism of action is immunosuppression and reduction of local inflammation
around dermal papilla [6]. Corticosteroids suppress the T-cell mediated immune action on the
hair follicles.
Topical steroids are indicated in alopecia areata, alopecia areata incognita, lichen planopilaris,
discoid lupus erythematosus, central centrifugal cicatricial alopecia, pseudopelade of brocq,
frontal fibrosing alopecia.
Treatment should be continued up to 3 months to see results in case of alopecia areata. Topical
steroids are less effective in cases of alopecia totalis and alopecia universalis. A local
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telangiectasia and atrophy are seen in cases of high and ultra-high potent steroids and with
long-term use of topical steroids.
2.3.2. Intralesional steroids
Intralesional steroids in alopecia areata are widely being used sine 50 years. They are the first-
line treatment therapy if alopecia areata is involved less than 50% of scalp area. Following
preparations are used:
• Triamcinolone acetonide: Concentration being used is 3–10 mg/ml and administering dose
is 0.1 ml/cm2 area.
• Triamcinolone hexacetonide
• Hydrocortisone acetate: Concentration being used is 25 mg/ml and administering dose is
0.1 ml/cm2 area.
It is injected into and just beneath the dermis. For an eyebrow and face, lower concentrations
2–3 mg/ml should be used and repeated after every 3–6 weeks. Hair growth is appreciated in
4–6 weeks. Local atrophy is reported with high concentrations of triamcinolone acetonide.
Severe cases of alopecia, alopecia totalis, alopecia universalis, rapidly progressing alopecia
areata and cases of greater than 2 years’ duration of the current episode respond poorly [7].
2.4. Topical sensitization/immunotherapy
Sensitizers are the chemicals which can initiate an allergic response and immunity on exposure
to the body. An inflammatory response is mounted by the immune system upon further
exposure. Happle, in 1980, described the mechanism of this inflammatory response in the
treatment of Alopecia areata that topical sensitizers redirect the inflammatory response in AA
away from the hair follicles and direct it towards themselves. This theory is unacceptable in all
cases as regrowth has been observed at distant sites or even at opposite sides from sensitizer
application, called as castling phenomenon.
Topical sensitizers should have following characteristics:
• It should be capable to produce immunomodulation.
• It should not be present in the normal natural environment as this may cause damage to a
person in his/her daily life exposures.
• It should not have cross-reactivity with other substances.
• It should be a safe chemical.
Followings are the common sensitizers being used:
• Dinitrochlorobenzene (DNCB)
• Squaric acid dibutylester (SADBE)
• Diphencyprone (DPCP)
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There are a variety of mechanisms of action of topical sensitization/immunotherapy:
• A decrease in CD4 to CD8 lymphocytes count from 4:1 to 1:1 is seen [8].
• The concept of ‘Antigenic Competition’ was proposed by Happle et al., that an allergic
reaction is generated which activates suppressor T cells that non-specifically inhibit the
immune reaction against a hair follicle. Topical Immunotherapy reduces the abnormal
expression of class I and II MHC molecules [8].
• Delayed-type hypersensitivity reactions to unrelated antigens occurring at remote sites
are reduced significantly.
• Topical sensitizers attract a new population of T cells into the treated areas and thus
helping in clearance of putative follicular antigen.
• Theory of ‘Cytokine Inhibitor’ was proposed by Buckley and Vivier that there was a
possible interference of contact allergens with the pre-existing pro-inflammatory cytokine,
and their continued production by follicular keratinocytes [8].
• The decrease in the raised interferon Y levels and increases in mRNA expression of
interleukin 2, 8, 10 and tumor necrosis factor-alpha in the lesional skin are seen.
Topical sensitizers are usually used in severe cases of Alopecia areata involving more than 50%
of total scalp having large patches or alopecia totalis. Overall topical sensitizers are well
tolerated. These are usually applied at the scalp. The initial concentration of DPCP is 0.001–
0.1% and is applied with a cotton-tipped applicator to an area of at least 10 cm2. The patient is
advised not to wash the area and avoid sunlight for first 48 h. The application is repeated
weekly to induce mild contact eczema and concentration is adjusted according to response. It
can take more than 5–7 days to see the significant eczematous response which indicates that
sensitization has taken place. Total hair growth rates are 77% with DPCP and 64% with
SADBE [9].
Side effects are persistent dermatitis, painful cervical lymphadenopathy, generalized eczema,
blistering, contact leukoderma and urticarial reaction. Fever, arthralgia and yellowish discol-
oration of gray hair are noted with DNCB [10].
2.5. Anthralin
Anthralin (1,8-dihydroxy-9-anthrone), also called as dithranol, is a natural anthraquinone
derivative obtained from the Araroba tree in Brazil as an old antipsoriatic agent but later on
found effective in alopecia areata too. It inhibits the proliferation of keratinocytes, prevents the
action of T-cells, and improves cell differentiation through blocking DNA synthesis and mito-
chondrial dysfunction [11]. Anthralin suppresses the release of IL-6 and TNF-alpha from
monocytes. A cosmetic response was seen in 25% of patients with severe alopecia areata
treated using 0.5–1% anthralin cream in an open study [12]. In another study, only 11%
cosmetically acceptable response observed in 51 patients of alopecia areata treated with a
combination of 5% minoxidil and 0.5% anthralin [13]. Anthralin should be used with high
enough concentration and in daily repeated applications to get a mild irritant reaction to get
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effective results. Severe irritation and staining of clothes and skin are most common side
effects.
2.6. Topical retinoids
Retinoids are a group of medicines derived from vitamin A. Common topical retinoids are
tretinoin, isotretinoin, adapalene, alitretinoin, tazarotene, and bexarotene. Initially, retinoids
were used for the treatment of acne but now a day due to their role in the induction of T-cell
apoptosis, they are being used in autoimmune alopecia like alopecia areata as we know
perifollicular and intrafollicular monocyte infiltrates contain primarily activated CD4+ and
CD8+ T-cells.
Hanson and colleagues note that topical bexarotene yielded significant hair regrowth when used
to treat patients with follicular mucinosis of folliculotropic Mycosis Fungoides [14]. Retinoids
regulate transcription signaling through the Retinoic Acid Receptor (RAR)-y, RAR-B and RAR-a
thus inhibiting proliferation and normalizing differentiation [15]. Topical retinol also increases
blood flow to hair follicles and encourage new blood vessel formation [16]. A 55% response in
alopecia areata is seen with 0.05% topical tretinoin as compare to 75% with topical betamet-
hasone dipropionate and 35% with 0.25% dithranol paste [17].
Yoo et al. investigated the combined effects of minoxidil and retinol on human hair growth
in vitro and on cultured human dermal papilla cells (DPCs) and epidermal keratinocytes (HaCaT)
and this combination promoted hair growth, hair shaft elongation than minoxidil alone [18].
Common side effects are irritation, dryness, stinging sensations, redness, swelling, peeling, blis-
tering and sunburn in the treated area and can aggravate eczema. Retinoids are contraindicated in
pregnancy and breastfeeding as negative animal studies are not always predictive of human
response.
2.7. Tacrolimus
Tacrolimus is a calcineurin inhibitor, and is being used for an immunosuppression since its
discovery in 1987 from a Japanese soil bacterium, Streptomyces tsukubaensis [19]. It is also
known as Fujimycin or FK506. The name tacrolimus is derived from “Tsukuba Macrolide
Immunosuppressant”.
Topical tacrolimus is mainly used in scarring alopecias like lichen planopilaris (LPP), central
centrifugal cicatricial alopecia, discoid lupus erythematosus (DLE), frontal fibrosing alopecia,
pseudopelade of Brocq.
Calcineurin, a serine–threonine phosphatase is activated via calmodulin by intracellular cal-
cium which is increased by activation of the T-cell receptor in T-cell. Calcineurin then dephos-
phorylates the nuclear factor of activated T-cells (NF-AT), which moves to the nucleus of T-cell
and increases the activity of genes coding for IL-2 and related cytokines [20].
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Tacrolimus by binding itself with an intracytoplasmic protein, FK506, blocks the dephosphor-
ylation of the nuclear factor of an activated T-cell thus preventing entry of nuclear factor into
the nucleus and limits lymphocyte proliferation, which is the predominant feature of scarring
alopecias [21].
Topical tacrolimus is available if different potencies i.e., 0.1, 0.03 and 0.3%. Regrowth of
terminal hair was noted in the outer region of a DLE patient with a monotherapy of topical
0.1% tacrolimus for 2 months [22]. Mild to moderate lichen planopilaris (LPP) involving less
than 10% of the scalp is best treated with tacrolimus [23].
The adverse effects of topical tacrolimus are uncommon but some reported are peeling and
burning at the area of application. Systemic absorption is undetectable even after topical use of
months [24].
2.8. Garlic
Garlic (Allium sativum) is a natural product species belonging to genus onion. The raw garlic is
composed of 59% water, 33% carbohydrates, 6% protein, 2% dietary fiber and less than 1% fat
[25, 26]. It is also rich in calcium, vitamin C, phosphorus, sulfur, zinc, and selenium. Besides its
use in alopecia areata (AA), androgenic alopecia (AGA), and scarring alopecias, it is also used
for the treatment of cardiovascular disorders, cancers, and the common cold.
Topical garlic is very effective for alopecia areata in children [27]. The combination of topical
garlic gel and betamethasone valerate cream was found more effective than betamethasone
valerate cream monotherapy in the treatment of localized alopecia areata [28].
Garlic, as well as being good for our body, can be really good for our scalp and hair. Followings
are the possible proposed mechanisms of action:
• It provides nourishment to hair follicles especially if the nourishment is blocked by
dihydro-testosterone (DHT) or bad diet.
• Garlic can stimulate the flow of blood to the scalp, thereby nourishing the hair, and thus
encouraging hair to grow and strengthen. Garlic is also good at adding body to hair, as
well as giving hair a nice gloss.
• It contains antiseptic properties and was used as antiseptic in World War II [29].
• It has antifungal properties and anti-inflammatory properties.
• Garlic reduces platelet aggregation [30].
• Hair, nail, and skin have high levels of sulfur and garlic is a rich source of sulfur.
Apply garlic gel/crushed garlic clove and rub it into the area of hair loss 60 min before you go
to sleep and wash the area in the next morning. Common side effects include irritation at the
site and with systemic absorption, bad smell from mouth and breath may occur.
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2.9. Ketoconazole
Ketoconazole is an imidazole antifungal being used mainly in seborrheic dermatitis and lichen
planopilaris and has anti-inflammatory properties too. Some hypothesize that ketoconazole
plays a role in the local disruption of the DHT pathway. These anti-androgen effects may
explain the side effect of gynecomastia in male patients taking oral ketoconazole. Combina-
tions with minoxidil and oral finasteride have shown comparable hair regrowth in both
groups than patients without ketoconazole shampoo.
2.10. Prostaglandin analogs
Prostaglandin analogs are synthetic drugs which bind to specific prostaglandin receptor sites
on cells to initiate the certain type of cellular activities. Most common are bimatoprost,
latanoprost, travoprost, and tafluprost. Initially, they were used to treating glaucoma and
eyelashes hypertrichosis and pigmentation notices in lashes and periocular area. They are
being used for the treatments of androgenic alopecia, alopecia areata, chemotherapy-induced
alopecia, vitiligo and hypopigmented scarring [31]. The extension of the duration of anagen
phase and the induction of telogen follicles into anagen phase are supposed mechanisms of
action of prostaglandin analogs [32]. The bimatoprost 0.03% lotion used in a mice study and
demonstrated a significant proportion of hair regrowth in 14 days [33]. Increased follicular
growth rate, number of anagen follicles, and the total number of hair were seen in a study of
bimatoprost on cultured scalp cells in patients with androgenic alopecia [34]. Blume-Peytavi
et al. demonstrated a significant increase in hair density with 24 weeks use of latanoprost 0.1%
at frontotemporal androgenic alopecia [35].
Bimatoprost and latanoprost were used by Ross et al. and Rosoborough et al. respectively in
cases of alopecia areata but did not display encouraging results even after use of 4 months.
Ochoa et al. suggested some benefit in less extensive cases of alopecia areata [36]. Besides local
erythematous reaction, no adverse events are reported yet.
3. Systemic treatment
As we know, there are many varieties of alopecia ranging from non-scarring alopecia like
AGA, AA, alopecia associated with iron deficiency, chemotherapy and thyroid diseases to
scarring alopecia like pseudopelade of Brocq, central centrifugal cicatricial alopecia, folliculitis
decalvans, acne keloidalis nuchae, lichen planopilaris, frontal fibrosing alopecia, discoid lupus
erythematosus (DLE), traumatic (injury, radiation and post-operative scarring alopecia) and
certain neoplasms so, in many cases only topical treatments are not so much fruitful thus
systemic remedies reserve their place in the treatment of alopecia. Available systemic treatments
include anti-androgens (finasteride, dutasteride, spironolactone, cyproterone acetate, flutamide),
systemic steroids, sulfasalazine, immunosuppressants (azathioprine & cyclosporine), methotrex-
ate, biological agents, photochemotherapy, low-level light therapy, excimer laser & excimer light,
vitamins & supplements, pharmacogenetics, wigs, hairpieces, and camouflages.
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3.1. Finasteride
Finasteride, 17B – (N-tert-butylcarbamoyl)-4-aza-5a-androst-1-en-3-one, is a synthetic and rostane
steroid and is analog of androgen steroid hormones like testosterone and DHT. It is a selective
and competitive inhibitor of the two isozymes of 5a-reductase, type II and III, present in certain
tissues like prostate, seminal vesicles, epididymis, skin, and hair follicles and responsible for the
conversion of testosterone in into DHT [37, 38]. The type II 5a-reductase isozyme is also respon-
sible for two-thirds of circulating DHT. Its half-life is 5–6 h in an adult, metabolized in liver, and
metabolites are eliminated 57% in the feces and 40% in urine [39].
Finasteride has been shown to increase the ratio of anagen to telogen hairs. It is effective in
increasing more hair weight than hair count [40]. Five-year results with 1 mg oral finasteride per
day in men with balding vertex showed significant greater hair count than placebo after 1 year,
hair growth peaked at 2 years and still stayed above baseline for 90% of patients after that [41].
A randomized placebo-controlled trial with finasteride 1 mg/day in men showed increased hair
growth inmen with modified Norwood-Hamilton grades II, II vertex, III or III vertex throughout
the second year of the study [42].
Approximately 2% of men reported one or more sexual side effects like decreased libido, erectile
dysfunction and ejaculation disorder. It is found that rate of these side effects became indistin-
guishable from a placebo after 2–4 years and usually got better with time. Gynecomastia and
mastalgia are reported in 0.4% of patients. Some cases of depression anxiety and suicidal
thoughts are also reported with finasteride.
3.2. Dutasteride
Dutasteride is a 5a reductase which inhibits all three forms of 5a reductase i.e., type I, II and III
in certain parts of the body like prostate and scalp leading to 98% reduction in DHT levels [43].
It is being used for the treatment of androgenic scalp hair loss in South Korea since 2009 and in
Japan since 2015 but in the USA it is often used off-label. In addition to inhibition of 5-alpha-
reductase, it also inhibits neurosteroidogenesis from testosterone which contains antidepres-
sant, anxiolytic and pro-sexual effects thus sexual dysfunction and depression have been seen
with 5-alpha-reductase inhibitors like dutasteride [44]. It is three times more potent than
finasteride in preventing 5 alpha-reductase type II and more than 100 times in type I [45]. Its
approved a daily dose is 0.5 mg/day, half-life 4–5 weeks, metabolized in the liver and excreted
mainly in feces. It is contraindicated in pregnant women. Side effects include decreased sperm
count, decreased semen volume and reduction in sperm motility, gynecomastia, menstrual
changes, and acne.
3.3. Spironolactone
Spironolactone is a synthetic steroid being used in the treatment of hypertension and different
cardiovascular disorders since long time and found having antiandrogen properties.
Spironolactone does not affect 5-alpha-reductase but acts by competitively blocking androgen
receptors in prostate and scalp. It also weakly inhibits testosterone synthesis. It is used in
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patterned hair loss and the women treated for 1 year with spironolactone 50–300 mg/day
showed less hair loss than the untreated group [46]. Side effects are dose-dependent and
mainly include menstrual irregularities, postmenopausal bleeding, breast tenderness or
enlargement and fatigue. The combination with oral contraceptives reduces its hormonal side
effects. No evidence of increased incidence of breast cancer found in women treated with
spironolactone [47].
3.4. Cyproterone acetate
Cyproterone acetate, a potent progestin, is an androgen receptor blocker which has anti
gonadotrophic effects too. Effects of cyproterone acetate are more prominent in women with
hyperandrogenism. Commonly dosages being used are 50–100 mg/day for the first 10 days of
each menstrual cycle while for postmenopausal women; it can be continuously given with or
without estrogens. Side effects include weight gain, breast tenderness, and loss of libido,
depression, and nausea. Feminization of male fetus is seen if cyproterone acetate is used
during pregnancy or if a woman becomes pregnant while taking it.
3.5. Flutamide
Flutamide, a non-steroidal antiandrogen, inhibits androgen uptake and nuclear binding of
androgen within the target tissue. Premenopausal women with female pattern hair loss
(FPHL) got good results with flutamide but in postmenopausal women, results were not
more than placebo with 1 mg/day dose [48]. Most common side effects are hepatotoxicity
and teratogenicity.
3.6. Systemic steroids
Systemic steroids are used in non-scarring alopecia like Alopecia areata and in scarring alope-
cia like variants of follicular lichen planus i.e., lichen planopilaris, frontal fibrosing alopecia
and DLE. With prednisone 0.5–1 mg/kg/day for 1–6 months, more than 25% hair regrowth was
seen [49, 50]. There are certain regimens other than daily dosages for systemic steroids like
mini pulse and pulse therapy. In a study, patients receiving prednisolone 200 mg once a week
(pulse therapy) for 3 months showed better hair regrowth at 6 months than placebo [51]. Mini
pulse therapy, tried in many skin diseases like alopecia areata and vitiligo, employs adminis-
tration of high dose oral corticosteroids on two consecutive days every week with a 5 days’
gap between the two pulses.
3.7. Sulfasalazine
Sulfasalazine was approved in the USA in 1950 and was considered a first-line therapy in
rheumatoid arthritis, ulcerative colitis, and Crohn’s disease and being used in psoriatic
arthritis, reactive arthritis, and alopecia areata. Sulfasalazine and its metabolites have immu-
nosuppressive, antibacterial, anti-inflammatory effects and inhibit the cysteine-glutamate
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antiporter (a system which imports the amino acid cysteine into cells) [52]. Around 90% of
sulfasalazine is metabolized in the colon by bacteria into a sulfapyridine and mesalazine and
then most of the sulfapyridine is absorbed and further metabolized and eliminated in urine.
The starting dose is 500 mg twice daily and gradually increased up to 1 g three times a day.
In one study, 23% of patients of alopecia areata showed a good response with sulfasalazine
therapy [53].
3.8. Immunosuppressants (azathioprine & cyclosporine)
Alopecia areata, a common non-scarring alopecia and scarring alopecia like follicular lichen
planus are T-cell mediated autoimmune processes; therefore, immunosuppressive therapies
are widely used in the treatments of alopecia. Most common immunosuppressants are azathi-
oprine and cyclosporine.
Azathioprine was made in 1957 and was the most effective and safe medicine being used to
prevent rejection following organ transplant, autoimmune diseases including rheumatoid
arthritis, pemphigus, systemic lupus erythematosus, Behcet’s disease, vasculitis, autoimmune
hepatitis, atopic dermatitis, myasthenia gravis, reactive lung diseases, alopecia areata, and
follicular lichen planus. Azathioprine inhibits purine synthesis, needed to produce DNA and
RNA, which are necessary for the production of white blood cells, thus causing immunosup-
pression A prospective study of adult patients with recalcitrant alopecia areata universalis
(unresponsive to oral corticosteroids) treated with oral 2.5 mg/kg/day for 6 months showed
52.3% mean global hair regrowth [54]. Side effects include nausea, vomiting, skin rash, acute
pancreatitis and bone marrow suppression.
Cyclosporine lowers the activity of T-cells by preventing the mitochondrial permeability tran-
sition pore from opening and inhibiting calcineurin-phosphatase pathway. A study of adult
patients (6 men, 1 woman) of alopecia universalis with oral cyclosporine 6 mg/kg/day for
12 weeks showed cosmetically acceptable hair regrowth in 50% of patients [55]. Side effects of
cyclosporine are gum enlargement, increased hair growth, convulsions, peptic ulcer, pancrea-
titis, increased cholesterol, numbness in lips and high blood pressure.
3.9. Methotrexate
Methotrexate is an anti-metabolite agent being widely used in chemotherapy and immunosup-
pression. It is mainly used in cases of cancers of breast, head & neck, bladder, blood (leukemia,
lymphoma), bones (osteosarcoma) and trophoblastic neoplasms. It is taken by oral or intrave-
nous route in weekly doses and acts by blocking the body’s use of folic acid. A study of 31
patients of alopecia areata with 10–25 mg/week methotrexate showed greater than 50% hair
regrowth in 67.7% of patients [56]. In another study, Joly reported good results in 22 patients
with alopecia areata, with or without systemic corticosteroids [57]. A further study of 31 patients
of alopecia areata, with 10–20 mg/week methotrexate with and without 1 mg/kg/day oral pred-
nisone taper, showed overall 71% response rate in 1–3 months and 36% of treated patients got
complete hair regrowth in 6–18 months [58].
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3.10. Biological agents
Biological agents are thought to act on tumor necrosis factor (TNF)-alpha and inter-cellular
adhesion molecules 1 in the treatment of alopecia areata. Common biological agents are etaner-
cept, efalizumab, alefacept, adalimumab, and infliximab. Different clinical trials are done but no
promising results gained yet.
3.11. Photochemotherapy
Both systemic and topical photochemotherapy is done by psoralen plus UV-A (PUVA) in the
treatment of alopecia areata. In a study, the initial response was 20–73% having relapse rate
50–88%. It interferes with the presentation of antigen to T-lymphocytes by depletion of
Langerhans cells. The recommended dose is 0.6 mg/kg and after 2 hours affected area is
exposed to UV-A for 20–30 min. In a study of PUVA in alopecia areata, hair regrowth is seen
up to 70% [59].
3.12. Low-level light therapy
Many products are available in the market utilizing low-energy laser beams but only one
device called Hairmax Lasercomb (Lexington International, Boca Raton, FL, USA) has got
510K FDA approval for use in hair loss as a medical device. Significant hair regrowth is seen
with a light device in the treatment of male pattern hair loss [60].
3.13. Vitamins & supplements
There are many products available in the market as vitamins and supplements but not prom-
ising trials available. Commonly in use products are Saw Palmetto, biotin, zinc, and iron. Saw
Palmetto inhibits the 5-alpha-reductase conversion of testosterone to DHT in the prostate [61].
A study of androgenic alopecia patients treated with Saw Palmetto showed increased hair
growth [62]. Biotin is used to treat onychoschizia but no clinical trials are available in hair loss.
Significant hair regrowth is seen with 30–50 mg/day zinc gluconate in patients of alopecia
areata [63].
3.14. Pharmacogenetics
Pharmacogenetics is an emerging medical field which provides information about inherited
genetic differences in metabolism, effects and adverse effects of a drug in genetically suscepti-
ble individuals. It is found that AGA has polychromosomal as well as polygenic origin
associated with increased levels of androgen receptors and 5-alpha-reductase in both men
and women. AR-DHT complex interacts with genomic DNA and initiates such cellular mech-
anisms that lead to AGA. By genetic studies, it is found that variations in the AR genes are
present on the long arm of the X chromosome and polymorphisms of the AR gene are
associated with hormonal and medical responses [64]. The repeat cytosine-adenine-guanine
(CAG) nucleotide sequences in the exon 1 of AR gene are related with androgen sensitivity to
the cell in men and women. Short CAG sequences are related with AGA. In pharmacogenetics,
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there are two research points: Identification of potential therapeutic targets and individual
variability in response to a specific drug. A strong correlation between the number of CAG
repeats in AR gene and response to finasteride therapy is found administering finasteride 1
mg/day and variable follow up between 12 and 24 months. In this study, it was discovered that
subjects with CAG repeat less than 21 showed greater response with finasteride than subjects
having CAG repeats more than 23 [65]. In a study of chemotherapy-induced alopecia, a strong
association in genetic variants near genes CACNB4 is found [66].
In the future, pharmacogenetics will help us to decide the treatments of an individual through-
out its life about the drugs which can or cannot be used on the basis of metabolism, safety, and
its effects. This analyzation of individual’s DNA will be done only once and will provide
information for the lifetime and as companies and laboratories that perform these testing can
do so at low prices, the field of pharmacogenetics will gain great acceptance in the day to day
medical treatments.
3.15. Hair transplant
In the hair transplant, follicular units are harvested from the safe zone at occiput and then
implanted at bald areas. There are two popular methods i.e., follicular unit transplant (FUT)
and follicular unit extraction (FUE). In FUT, a strip is harvested from safe zone and then
follicular units are prepared by slivering the strip under a microscope. In FUE, follicular units
are extracted one by one with 0.7–1.0 mm wide and 4–6 mm lengthy sharp or blunt punches
which may be manual or motorized and then these follicular units are implanted at bald areas.
4. Conclusions
It is concluded that minoxidil, finasteride, and PRP are the best treatments for androgenic
alopecia and alopecia areata while steroids, sensitizers, and immunosuppressants are mainly
used in autoimmune alopecia. Hair transplant is the best option in cases of androgenic alope-
cia and stable forms of scarring alopecia. Pharmacogenetics is a newly emerging medical field
which can change the future of medical treatments.
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